Clinical trial NCT03144596 - References

Benign Prostatic Hyperplasia — The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

Citation(s)

•   Abdel-Aziz S, Mamalis N
  Intraoperative floppy iris syndrome. Curr Opin Ophthalmol. 2009 Jan;20(1):37-41. doi: 10.1097/ICU.0b013e32831bc0ad. Review.
•   Berry SJ, Coffey DS, Walsh PC, Ewing LL
  The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9.
•   Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG
  Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013 Nov 5;347:f6320. doi: 10.1136/bmj.f6320.
•   Chang DF, Braga-Mele R, Mamalis N, Masket S, Miller KM, Nichamin LD, Packard RB, Packer M; ASCRS Cataract Clinical Committee
  . ASCRS White Paper: clinical review of intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2008 Dec;34(12):2153-62. doi: 10.1016/j.jcrs.2008.08.031. Review.
•   Chang DF, Campbell JR
  Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005 Apr;31(4):664-73.
•   Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H
  Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther. 2001 May;23(5):727-43.
•   de Mey C
  alpha(1)-blockers for BPH: are there differences? Eur Urol. 1999;36 Suppl 3:52-63. Review.
•   Dunn CJ, Matheson A, Faulds DM
  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002;19(2):135-61. Review.
•   Filson CP, Hollingsworth JM, Clemens JQ, Wei JT
  The efficacy and safety of combined therapy with a-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol. 2013 Dec;190(6):2153-60. doi: 10.1016/j.juro.2013.05.058. Epub 2013 May 30.
•   Gu N, Kim J, Lim KS, Shin KH, Kim TE, Lee B, Shin SG, Jang IJ, Yu KS
  Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study. Clin Ther. 2012 Sep;34(9):1929-39. doi: 10.1016/j.clinthera.2012.08.002. Epub 2012 Aug 24.
•   Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M
  Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994 Nov;113(3):723-8.
•   Hollingsworth JM, Wilt TJ
  Lower urinary tract symptoms in men. BMJ. 2014 Aug 14;349:g4474. doi: 10.1136/bmj.g4474. Review.
•   Kerimoglu H, Zengin N, Ozturk B, Gunduz K
  Unilateral chemosis, acute onset myopia and choroidal detachment following the use of tamsulosin. Acta Ophthalmol. 2010 Mar;88(2):e20-1. doi: 10.1111/j.1755-3768.2008.01503.x. Epub 2009 Mar 19.
•   Kiel JW, Lovell MO
  Adrenergic modulation of choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci. 1996 Mar;37(4):673-9.
•   Konno F, Takayanagi I
  Characterization of postsynaptic alpha 1-adrenoceptors in the rabbit iris dilator smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):271-6.
•   Mamalis N
  Intraoperative floppy-iris syndrome associated with systemic alpha blockers. J Cataract Refract Surg. 2008 Jul;34(7):1051-2. doi: 10.1016/j.jcrs.2008.05.017.
•   McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT
  Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5):1793-803. doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.
•   Nickla DL, Wallman J
  The multifunctional choroid. Prog Retin Eye Res. 2010 Mar;29(2):144-68. doi: 10.1016/j.preteyeres.2009.12.002. Epub 2009 Dec 29. Review.
•   Nieminen T, Ylitalo R, Kööbi T, Ylitalo P, Kähönen M
  The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. Eur Urol. 2005 Mar;47(3):340-5. Epub 2004 Dec 29.
•   Oelke M, Gericke A, Michel MC
  Cardiovascular and ocular safety of a1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014 Sep;13(9):1187-97. doi: 10.1517/14740338.2014.936376. Epub 2014 Jul 29. Review.
•   Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F
  Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012 Oct;13(14):2085-96. doi: 10.1517/14656566.2012.714368. Epub 2012 Aug 28. Review.
•   Schwinn DA, Michelotti GA
  alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000 Apr;85 Suppl 2:6-11. Review.
•   Shapiro BL, Petrovic V, Lee SE, Flach A, McCaffery S, O'Brien JM
  Choroidal detachment following the use of tamsulosin (Flomax). Am J Ophthalmol. 2007 Feb;143(2):351-3. Epub 2006 Oct 23.
•   Tanabe H, Ito Y, Iguchi Y, Ozawa S, Ishikawa K, Terasaki H
  Correlation between cross-sectional shape of choroidal veins and choroidal thickness. Jpn J Ophthalmol. 2011 Nov;55(6):614-9. doi: 10.1007/s10384-011-0079-2. Epub 2011 Aug 27.
•   Vance SK, Imamura Y, Freund KB
  The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina. 2011 Feb;31(2):332-5. doi: 10.1097/IAE.0b013e3181eef0ae.
•   Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C
  The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin. 2013 Mar;29(3):279-87. doi: 10.1185/03007995.2013.766594. Epub 2013 Jan 29. Review.

The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia

Details for clinical trial NCT03144596